Iovance: Cell Therapy Pioneer Finally Scaling – Now the Lung Cancer Market is in Focus

Disappointed expectations caused the Iovance stock price to plummet from $18.33 in March 2024 to $1.64 in early May 2025. Initially, the future looked promising. In February 2024, the company received accelerated FDA approval for the cell therapy Amtagvi. In 2023, Iovance also recorded its first revenues of $1.2 million, which were projected to rise to $164 million in 2024 and $263.5 million (+61%) in 2025. However, investor expectations could not be met due to the complexities of manufacturing and scalability. The significantly fallen stock price,...